Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CD4<sup>+</sup> T cells persist with their Eomes.

Immunity·2026
Same author

Differential stem-like potential of naïve and memory CD8 T cells after chronic infection.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

New insights into progenitor exhausted T cell populations.

Nature reviews. Immunology·2026
Same author

Simultaneous TCR and IL-2 agonism selectively enhances epitope-specific CD8 T-cell responses during chronic viral infection.

Journal of virology·2026
Same author

Neuroprotective Phytochemicals Targeting Amyloid and Tau Pathologies.

Current topics in medicinal chemistry·2026
Same author

Coadministration of rapamycin with a DNA/MVA SIV vaccine improves memory CD8+ T cell response.

JCI insight·2026

Related Experiment Video

Updated: May 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Manipulating the PD-1 pathway to improve immunity.

Alice O Kamphorst1, Rafi Ahmed

  • 1Emory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, 1510 Clifton Road, Atlanta, GA 30322, USA.

Current Opinion in Immunology
|April 16, 2013
PubMed
Summary

Programmed cell death protein 1 (PD-1) blockade rescues exhausted T cells, offering cancer and infection treatments. Further research into PD-1

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Related Experiment Videos

Last Updated: May 12, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • Programmed cell death protein 1 (PD-1) is an inhibitory receptor on T cells, crucial for immune regulation.
  • Sustained PD-1 expression leads to T cell dysfunction, impacting chronic infections and cancer immunity.
  • Current therapies blocking PD-1 signaling effectively rescue exhausted T cells.

Purpose of the Study:

  • To investigate the role of PD-1 in initiating immune responses.
  • To explore the potential of combining PD-1 blockade with therapeutic vaccination for enhanced T cell rescue.
  • To understand PD-1 pathway modulation of humoral responses involving B cells and Tfh cells.

Main Methods:

  • The study reviews existing literature on PD-1 expression and function.
  • It analyzes the impact of PD-1 blockade on T cell exhaustion and immune responses.
  • The research considers the role of PD-1 in both cellular and humoral immunity.

Main Results:

  • PD-1 is induced early in T cell priming, suggesting a role in immune response initiation.
  • Combining PD-1 blockade with vaccination may improve T cell rescue.
  • The PD-1 pathway influences humoral immunity through B cells and Tfh cells.

Conclusions:

  • While PD-1 blockade is a powerful immunotherapy for rescuing exhausted T cells, its full potential remains to be exploited.
  • Further investigation into PD-1's role in immune response initiation and its modulation of humoral immunity is warranted.
  • Optimizing PD-1 pathway manipulation could lead to more effective treatments for cancer and chronic infections.